Display Settings:

Format

Send to:

Choose Destination
Expert Opin Biol Ther. 2009 Aug;9(8):1099-106. doi: 10.1517/14712590903055011.

The role of natalizumab in hematopoietic stem cell mobilization.

Author information

  • 1Heinrich-Heine-University, Department of Hematology, Oncology and Clinical Immunology, Duesseldorf, Germany. Frank.Neumann@med.uni-duesseldorf.de

Abstract

The humanized monoclonal very late antigen 4 (VLA-4) antibody natalizumab is FDA approved for the treatment of patients with multiple sclerosis and Crohn's disease. In this review we focus on its role in the context of hematopoietic stem cell transplantation and stem cell diseases. The use of natalizumab alone or in combination with either cytotoxic drugs or other antibodies might be a new modality for stem cell mobilization and a therapeutic option for patients with hematologic malignancies.

PMID:
19566481
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk